Adam Parker

THE WRITER IS FOUNDER AND CHIEF EXECUTIVE OF TRIVARIATE RESEARCH

It is not advised for a company to buy one of a similar size, or for investors to be sold on the potential for synergies in such a deal.
WEALTH & INVESTING

Why investors should be wary of ‘mergers of equals’

The stock price of the combined company tends to underperform after the deal